Group B Streptococcus Infection Treatment Market Set To Grow From $1.36 Billion In 2026 To $1.89 Billion By 2030 At A CAGR Of 8.6%
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Group B Streptococcus Infection Treatment Market Revenue Outlook: What CAGR Is Expected Through 2030?
The market size for Group B Streptococcus infection treatment has seen considerable growth in recent years. It is anticipated to expand from $1.26 billion in 2025 to $1.36 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.3%. The expansion observed in prior periods can be attributed to a heightened awareness of neonatal infections, the extension of prenatal care programs, the widespread application of beta-lactam antibiotics, an increase in hospital-based screening protocols, and the accessibility of microbiological testing services.
The group b streptococcus infection treatment market size is set to experience robust expansion over the forthcoming years. It is projected to reach $1.89 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.6%. This anticipated growth during the forecast period is fueled by the accelerating development of gbs vaccines, increasing uptake of point-of-care diagnostics, a heightened focus on antimicrobial resistance management, the expansion of molecular testing infrastructure, and a growing emphasis on preventive maternal healthcare. Significant trends anticipated in this period encompass the rising adoption of rapid molecular diagnostic testing, a greater concentration on prenatal gbs screening programs, the expanding implementation of antibiotic stewardship protocols, the broadening of pipeline therapies aimed at gbs prevention, and enhanced monitoring of maternal and neonatal outcomes.
Download A Free Sample Report For Comprehensive Market Insights:
Group B Streptococcus Infection Treatment Market Opportunity Drivers: What Is Creating New Revenue Potential?
The increasing healthcare expenditure is anticipated to drive the expansion of the group B streptococcus infection treatment market in the future. Healthcare expenditure encompasses all financial resources allocated to medical services, preventative measures, pharmaceutical products, healthcare facilities, and associated health activities aimed at preserving or enhancing public health. This expenditure is escalating primarily due to the growing occurrence of chronic and infectious diseases, which in turn fuels consistent demand for extended treatments, sophisticated therapies, and ongoing medical attention. Increased healthcare spending bolsters the group B Streptococcus infection treatment by facilitating greater investment in prenatal screening, clinical infrastructure, and vaccine research. These collective efforts lead to better early detection, prevention, and successful management of GBS infections in both mothers and newborns. For example, in April 2025, as reported by the Office for National Statistics, a UK-based government organization, total healthcare spending saw a rise of 6.5% from 2023 to 2024, demonstrating an acceleration when compared to the 6.3% growth recorded in 2023. Consequently, the upward trend in healthcare expenditure is a significant factor propelling the growth of the group B streptococcus infection treatment market.
#Group B Streptococcus Infection Treatment Market Segment Landscape And Growth Potential
The group b streptococcus infection treatment market covered in this report is segmented –
1) By Treatment Type: Antibiotic Therapy; Intravenous Immunoglobulin (IVIG); Experimental Therapies
2) By Drug Class: Beta-Lactam Antibiotic; Clindamycin And Alternatives; Pipeline Therapies
3) By Route of Administration: Oral Administration; Intravenous Administration; Topical Application
4) By Patient Type: Newborns; Pregnant Women; Immunocompromised Patients; Elderly Population
5) By End User: Hospitals; Clinics; Research Institutions; Home Care Settings
Subsegments:
1) By Antibiotic Therapy: Penicillin Based Antibiotics; Cephalosporin Antibiotics; Macrolide Antibiotics; Aminoglycoside Antibiotics
2) By Intravenous Immunoglobulin (IVIG): Standard Polyclonal Immunoglobulin; High Dose Immunoglobulin Therapy; Adjunctive Immunoglobulin Therapy
3) By Experimental Therapies: Vaccine Based Therapies; Monoclonal Antibody Therapies; Bacteriophage Therapies; Immunomodulatory Therapies
Group B Streptococcus Infection Treatment Market Innovation Trends Driving Future Development
Major companies operating in the group B streptococcus infection treatment market are focusing on developing innovative products, such as polysaccharide conjugate vaccines, to reduce asymptomatic bacterial carriage. These immunizations, known as polysaccharide conjugate vaccines, chemically link bacterial surface sugars to a carrier protein to enhance immune recognition and generate a strong, long-lasting protective response, especially in infants and young children. For instance, in September 2023, Omniose, a US-based biotechnology company, announced a grant award of up to $3.0 million from the National Institute of Allergy and Infectious Diseases at the U.S. National Institutes of Health to support the development of a Group B Streptococcus (GBS) vaccine. The vaccine’s unique feature lies in its aim to achieve high efficacy through a highly simplified manufacturing approach. Omniose’s platform leverages synthetic biology and a one-step enzymatic process within a single re-engineered E. coli cell to produce GBS polysaccharide conjugate vaccines, eliminating conventional chemical conjugation steps. This process preserves 100% of sialic acid residues on each capsular polysaccharide, a factor shown to be critical for inducing strong functional antibody responses against specific GBS serotypes.
Group B Streptococcus Infection Treatment Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the group b streptococcus infection treatment market are Merck & Co. Inc., Pfizer Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Biological E. Limited, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., Vaxcyte Inc., Bharat Biotech International Limited, Clover Biopharmaceuticals Ltd., Biovac Institute (Pty) Ltd., Inventprise Inc., BioNet Asia Co. Ltd., GeneOne Life Science Inc., Alopexx Enterprises LLC, Wellstat Vaccines LLC, MinervaX ApS, and ShanghAI Zerun Biotechnology Co. Ltd.
Access The Complete Group B Streptococcus Infection Treatment Market Report:
Group B Streptococcus Infection Treatment Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the group B streptococcus infection treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the group b streptococcus infection treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
